Skip to Main Content

Paper Details

Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.
Cell Rep Med
5
2021
Cabozantinib, ERK, MAPK, MEK, MET, NCCRCC, SRC, VEGFR, cabozantinib, dasatinib, human, human kidney cancer cells, kidney cancer, non-clear cell renal cell carcinoma, tumor
Author NameAffiliation
Anna RitzReed College
Laura M HeiserKnight Cancer Institute, Oregon Health and Science University
Laura M HeiserOregon Health and Science University Center for Spatial Systems Biomedicine
Laura M HeiserKnight Cancer Institute, Oregon Health and Science University
Laura M HeiserOregon Health and Science University Center for Spatial Systems Biomedicine
George V ThomasKnight Cancer Institute, Oregon Health and Science University
George V ThomasOregon Health and Science University
  • 1 - 7

Datasets

Release 1.2